These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39178176)

  • 1. Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients.
    Iwatani T; Sasaki K; Machida R; Shien T; Hara F; Fujisawa T; Takano Y; Kobayashi Y; Saimura M; Koizumi K; Terada M; Sasada S; Saito K; Sumiyoshi M; Iwata H
    Jpn J Clin Oncol; 2024 Oct; 54(10):1093-1099. PubMed ID: 39178176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
    Biskupiak J; Oderda G; Brixner D; Tang D; Zacker C; Dalal AA
    J Manag Care Spec Pharm; 2019 Aug; 25(8):859-866. PubMed ID: 31347980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group.
    Takashima A; Ishiguro M; Sasaki K; Machida R; Nagashima F; Imaizumi J; Hamaguchi T; Yamamoto Y; Masuishi T; Asayama M; Ueno H; Shinozaki K; Kudo T; Machida N; Matsuoka H; Ishida H; Yamaguchi T; Nogami H; Yamada T; Takegawa N; Kito Y; Tonoike Y; Sawada R; Tsukamoto S; Kanemitsu Y;
    Jpn J Clin Oncol; 2024 Oct; 54(10):1107-1114. PubMed ID: 39210583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22.
    Imaoka H; Sasaki K; Machida R; Nagano H; Satoi S; Ikeda M; Kobayashi S; Yamashita T; Okusaka T; Ido A; Hatano E; Miwa H; Ueno M; Nakao K; Shimizu S; Kuramochi H; Sakamori R; Tsumura H; Okano N; Shioji K; Shirakawa H; Akutsu N; Tsuji K; Ishii H; Umemoto K; Asagi A; Ueno M;
    Jpn J Clin Oncol; 2024 Oct; 54(10):1071-1077. PubMed ID: 38843879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.
    Dalal AA; Gagnon-Sanschagrin P; Burne R; Guérin A; Gauthier G; Small T; Niravath P
    Adv Ther; 2018 Jun; 35(6):768-778. PubMed ID: 29869106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy.
    Yajima S; Shimizu H; Sakamaki H; Ikeda S; Ikegami N; Murayama JI
    BMC Health Serv Res; 2016 Jan; 16():2. PubMed ID: 26728154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Yokoyama K; Wasano K; Sasaki K; Machida R; Nakahira M; Kitamura K; Sakagami T; Takeshita N; Ohkoshi A; Suzuki M; Tateya I; Morishita Y; Sekimizu M; Nakayama M; Koyama T; Shibata H; Miyamaru S; Kiyota N; Hanai N; Homma A
    Jpn J Clin Oncol; 2024 Oct; 54(10):1115-1122. PubMed ID: 39206595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group.
    Motomura K; Sasaki K; Sugii N; Yamaguchi S; Inoue H; Oshima A; Tanaka K; Otani Y; Shirahata M; Shibahara I; Nagane M; Tsuzuki S; Matsutani T; Tsukamoto Y; Kijima N; Asano K; Ohno M; Inoue A; Mineharu Y; Miyake K; Mitobe Y; Hanihara M; Kawanishi Y; Deguchi S; Saito M; Matsuda R; Ujifuku K; Arita H; Sato Y; Yamashita S; Yonezawa U; Yamaguchi J; Momii Y; Ogawa T; Kambe A; Ohba S; Fukai J; Saito N; Kinoshita M; Sumi K; Otani R; Uzuka T; Takebe N; Koizumi S; Saito R; Arakawa Y; Narita Y;
    Jpn J Clin Oncol; 2024 Oct; 54(10):1123-1131. PubMed ID: 39223700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
    Raphael J; Helou J; Pritchard KI; Naimark DM
    Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world treatment trends for patients with advanced prostate cancer and renal cell carcinoma and their cost-a survey in Japan.
    Osawa T; Sasaki K; Machida R; Matsumoto T; Matsui Y; Kitamura H; Nishiyama H
    Jpn J Clin Oncol; 2024 Oct; 54(10):1062-1070. PubMed ID: 38843876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer.
    Li N; Du EX; Chu L; Peeples M; Xie J; Barghout V; Tang DH
    Expert Opin Pharmacother; 2017 Aug; 18(12):1167-1178. PubMed ID: 28699804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group.
    Nishina T; Boku N; Kurokawa Y; Sasaki K; Machida R; Yoshikawa T
    Jpn J Clin Oncol; 2024 Oct; 54(10):1100-1106. PubMed ID: 39180720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Zhang B; Long EF
    Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group).
    Watanabe K; Sasaki K; Machida R; Shimizu J; Yamane Y; Tamiya M; Saito S; Takada Y; Yoh K; Yoshioka H; Murakami H; Kitazono S; Goto Y; Horinouchi H; Ohe Y
    Jpn J Clin Oncol; 2024 Oct; 54(10):1084-1092. PubMed ID: 39158350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.
    Chang SH; Svensson M; Hsin-Min Wang G; Wang Y; Kang HR; Park H
    J Manag Care Spec Pharm; 2024 Sep; 30(9):942-953. PubMed ID: 39213142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
    Seki H; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
    Anticancer Res; 2022 Feb; 42(2):1099-1106. PubMed ID: 35093912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
    Matter-Walstra K; Ruhstaller T; Klingbiel D; Schwenkglenks M; Dedes KJ
    Breast Cancer Res Treat; 2016 Jul; 158(1):51-57. PubMed ID: 27277747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.